As of 2026-07-13 · Last updated: 2026-07-14 · Source: SEC EDGAR (XBRL companyfacts, CIK 0000001800), stockanalysis (price, statistics, financial statements, ratios, consensus), Company IR · Prices & financials updated periodically (not real-time) · Information tool (not investment advice)
Debt is smaller than equity and it can meet short-term obligations.
Metrics · D/E ~65% · Current Ratio 1.39
💲Is the price expensive now?
Not cheap (fair to slightly pricey)
Because it is a good, popular company, those expectations are already priced in.
Metrics · P/E 26.3 · P/B 3.1
💡Four segments diversify risk. Solid at 19% operating margin and ~12% ROE, a 54-year Dividend King, with debt a moderate 0.65x equity.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: stockanalysis (margins, debt, liquidity, P/B, ROE are TTM), as of 2026-07-13
Business Summary · Key Value Metrics
A diversified healthcare company spanning four segments: Diagnostics, Medical Devices (including the FreeStyle Libre continuous glucose monitor), Nutrition (Similac, Ensure), and Established Pharmaceuticals. TTM revenue $45.1B with a 19.0% operating margin. In 2013 it spun off its research-based pharma arm as AbbVie.
Current Price
$92.20
-1.84%-$1.73· Close 2026-07-13
Analyst Consensus Target (external reference)
$116.72
Avg. of 28 external analysts · stockanalysis (28-analyst consensus, Buy)
P/E (TTM)
26.3x
TTM
ROE
12.3%
TTM
Operating Margin
19.0%
TTM
Net Margin
13.9%
TTM
Dividend Yield
2.73%
54 years of raises
Market Cap
$160.6B
As of 2026-07-13
Economic Moat · Key Business Segments
Abbott is diversified across four segments — Diagnostics, Medical Devices, Nutrition, and Established Pharmaceuticals — so weakness in one is cushioned by the others. Its FreeStyle Libre continuous glucose monitor (CGM) holds a leading position in the global diabetes-management market, and Abbott is a Dividend King that has raised its payout for 54 consecutive years (source: company IR · stockanalysis).
Business diversification
Four segments — diagnostics, devices, nutrition, and established pharma — so weakness in one is offset by the others.
FreeStyle Libre leadership
A market-leading continuous glucose monitor (CGM) and a key beneficiary of fast-growing diabetes management.
Emerging-market distribution
Established Pharmaceuticals and Nutrition reach 160+ emerging-market countries through channels rivals struggle to replicate.
Dividend stability
54 consecutive years of dividend increases earn Dividend King status, with a payout ratio near 69%.
10-Year Financial Trends
Revenue grew at a 9-year CAGR of +8.7% (2016 $20.9B → 2025 $44.3B), boosted by the 2017 acquisitions of St. Jude Medical and Alere. Operating income (+10.9%), net income (+18.6%), and EPS (+16.5%) rose alongside it. Note, though, that 2024 net income of $13.4B (diluted EPS $7.64) reflected a roughly $6.4B one-time net tax credit; results normalized in 2025 to $6.5B net income (diluted EPS $3.72) (source: SEC EDGAR 10-K · company earnings).
9-Year CAGR: Revenue +8.7% · Operating Income +10.9% · Net Income +18.6% · EPS +16.5%
Sources: SEC EDGAR XBRL (companyfacts, CIK 0000001800) · stockanalysis · company earnings releases (8-K). Fiscal-year (December) GAAP basis; EPS is diluted. P/E and ROE cover the last 5 years (stockanalysis) due to data limits, while revenue, operating income, EPS, and operating margin span 10 years. The 2018 revenue-recognition change (ASC 606) and the St. Jude Medical and Alere acquisitions enlarged the 2017→2018 top line. In 2024, GAAP net income, EPS, and ROE surged on a roughly $6.4B one-time tax benefit before normalizing in 2025.
Mega-Cap Value Metric Comparison
Johnson & Johnson has the highest operating margin (26.9%), while Abbott (19.0%) and Medtronic (20.0%) are similar. Johnson & Johnson trades at the highest P/E, carrying a premium, and Medtronic offers the highest dividend yield (3.39%) (source: stockanalysis).
Infant-formula (NEC) litigation— Numerous lawsuits allege that a preterm-infant formula (Similac Special Care 24) caused necrotizing enterocolitis (NEC). Large damage risks continue, including a 2024 Missouri jury verdict of $495M (upheld on appeal) and a $70M Illinois verdict in April 2026.Source: Court rulings · media reports
●
GAAP earnings volatility— 2024 GAAP net income and EPS spiked on a roughly $6.4B one-time tax benefit before normalizing in 2025. Reading annual GAAP figures alone can misrepresent the true operating trend.Source: SEC EDGAR
●
Intensifying device competition— FreeStyle Libre faces intensifying competition in the continuous glucose monitor (CGM) market from Dexcom and others.Source: Company 10-K Risk Factors
●
Currency risk— With a high share of overseas sales, a stronger dollar can weigh on revenue and profit through translation losses.Source: Company 10-K Risk Factors
✦ ValueCrab Dashboard PreviewABT $92.2 -1.84% · as of 2026-07-13
Q. What are Abbott's (ABT) key value-investing metrics?P/E (TTM) 26.3, ROE 12.3%, operating margin 19.0%, net margin 13.9%, dividend yield 2.73%, and a 9-year revenue CAGR of +8.7% (source: stockanalysis, as of 2026-07-13).
Q. How is Abbott as a dividend stock?As a Dividend King that has raised its payout for 54 consecutive years, its dividend stability is very high. The current yield is about 2.73% with a payout ratio near 69%. (This is informational and not a buy or sell recommendation.)
Q. Why did 2024 net income suddenly spike?2024 GAAP net income of $13.4B (diluted EPS $7.64) reflected a roughly $6.4B one-time tax benefit. In 2025, net income returned to a normal $6.5B (diluted EPS $3.72) (source: SEC EDGAR 10-K).
Q. Who are the main competitors?Among healthcare large caps, Johnson & Johnson (JNJ) is a key peer, and in medical devices, Medtronic (MDT). Abbott stands out for its diversification across four businesses: diagnostics, devices, nutrition, and established pharmaceuticals.